AAVXF Stock: Abivax S.A. Stock Price, Analysis & Insights
Get live aavxf stock price $86.10, comprehensive Abivax S.A. stock analysis, charts, news, and expert forecast. Real-time aavxf stock data and investment insights.
Company Overview
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Company Information
- CEO
- Marc M. P. de Garidel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
Contact Information
- Website
- https://www.abivax.com
- Address
- 5, rue de la Baume
- Country
- FR
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 6.51B market capitalization
- Trading Volume: 100 shares traded today
- Price Range: 52-week range of $5.81 - $88.90
- Exchange: Listed on Other OTC
Financial Metrics
Market Analysis for Abivax S.A.
Abivax S.A. (AAVXF) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 6.51B, the company represents a significant player in its market. The stock is currently trading at $86.10 with a positivedaily change of 0.00%.
The company's 69 employee base and presence on the Other OTCexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -23.78, beta of 0.13, and 52-week price range from $5.81 to $88.90when evaluating investment opportunities.
Why Invest in Abivax S.A.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (Other OTC)
- • Experienced leadership under Marc M. P. de Garidel
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.